HCV cure for everyone or which challenges remain?
Following the approval of the first HCV direct-acting antiviral (DAA) in 2011, an unforeseen revolution in the treatment of chronic hepatitis C has taken place. In 2015 several all-oral DAA regimens, combining agents from different families (NS5B nucleotide inhibitors, NS5B non-nucleoside inhibitors...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-04-01
|
Series: | Journal of Virus Eradication |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S205566402030491X |